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Objectives/Hypothesis: To determine if tumor biomarkers were predictive of outcome in a prospective cohort of
patients with advanced larynx cancer treated in a phase II clinical trial.
Study Design: Prospectively collected biopsy specimens from 58 patients entered into a Phase II trial of organ preserva-
tion in advanced laryngeal cancer were evaluated for expression of a large panel of biomarkers, and correlations with out-
come were determined.
Methods: Tissue microarrays were constructed from pretreatment biopsies and stained for cyclin D1, CD24, EGFR,
MDM2, PCNA, p53, survivin, Bcl-xL, Bcl-2, BAK, rhoC, and NFjB. Pattern of invasion and p53 mutations were assessed. Corre-
lations with overall survival (OS), disease-specific survival (DSS), time free from indication of surgery, induction chemother-
apy response, and chemoradiation response were determined. Cox models were used to assess combinations of these
biomarkers.
Results: Low expression of BAK was associated with response to induction chemotherapy. Low expression of BAK and
cytoplasmic NFjB was associated with chemoradiation response. Aggressive histologic growth pattern was associated with
response induction chemotherapy. Expression of cyclin D1 was predictive of overall and disease-specific survival. Overexpres-
sion of EGFR was also associated with an increased risk of death from disease. Bcl-xL expression increased significantly in
persistent/recurrent tumors specimens when compared to pretreatment specimens derived from the same patient
(P5 0.0003).
Conclusions: Evaluation of biomarker expression in pretreatment biopsy specimens can lend important predictive and
prognostic information for patients with advanced larynx cancer.
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Level of Evidence: N/A.
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INTRODUCTION
Over 10,000 people are diagnosed with larynx can-
cer in the United States each year and nearly 4,000 lar-
ynx cancer patients die each year.1 Conventional
treatments that combine radical resection and radiation
therapy for larynx cancers are associated with profound
functional morbidity that affect quality of life. Most
patients have advanced (stage III & IV) disease at the
time of diagnosis. The poor cure rates and morbidity of
surgical treatment prompted the development of chemo-
therapy trials designed to offer larynx preservation.
However, the resistance of some tumors to chemotherapy
and radiation limits the effectiveness of organ sparing
therapy, contributes to early recurrence and death, and
underscores the need to identify and overcome resistance
cmechanisms. Chemoradiation approaches have been
unsuccessful at improving overall survival compared to
primary surgery2,3; however, tumor response to induc-
tion chemotherapy has been predictive of patients with a
favorable response to chemoradiation therapy.4
The aim of this research is to identify biomarkers
that predict treatment response as well as prognosis.
This approach will inform the selection of best treatment
options for patients and limit unnecessary patient
TRIOLOGICAL SOCIETY
CANDIDATE THESIS
From the Department of Biostatistics, Comprehensive Cancer Cen-
ter (E.B., J.L., J.T.); the Department of Periodontics and Oral Medicine,
Dental School (N.D’S., K.C., P.K.); the Department of Otolaryngology–Head
and Neck Surgery, Medical School (C.R.B., B.K., R.K., G.T.W., T.N.T., M.E.P.P.,
D.B.P., N.D.H., J.S.M., T.E.C.); the Department of Pathology, Medical School
(C.K.); the Department of Internal Medicine, Division of Hematology/
Oncology, Medical School (S.U., F.W.); the Department of Radiation Oncol-
ogy, Medical School (A.E.), University of Michigan, Ann Arbor, Michigan.
Current affiliations: Department of. Otolaryngology (B.K., T.N.T.), Ohio
State University, Columbus, Ohio; Louisiana State University (K.C.),
New Orleans, Louisiana, U.S.A.
Editor’s Note: This Manuscript was accepted for publication May
20, 2013.
All work was conducted at the University of Michigan
Presented at the Combined Triological Society Section Meetings,
Miami, Florida, U.S.A., February 26–28, 2012.
Study supported by the University of Michigan Head and Neck
Cancer SPORE (NCI P50 CA97248) and the University of Michigan
Comprehensive Cancer Center Core Grant (NCI P30 CA46592). The
authors have no other funding, financial relationships, or conflicts of
interest to disclose.
Send correspondence to Carol R. Bradford, MD, Charles J. Krause,
MD, Collegiate Professor and Chair, Department of Otolaryngology–
Head and Neck Surgery, University of Michigan, 1904 Taubman Center,
1500 E. Medical Center Drive, Ann Arbor, MI 48109-5312. E-mail:
cbradfor@med.umich.edu
DOI: 10.1002/lary.24245
Laryngoscope 124: January 2014 Bradford et al.: Biomarkers in Advanced Larynx Cancer
179
morbidity due to ineffective therapeutic approaches. In
addition, the identification of biomarkers will lead to
pathways responsible for treatment resistance and will
allow future development of novel personalized
approaches tailored to tumor biology.
Herein, a panel of biomarkers was evaluated to
determine their predictive and prognostic significance in
advanced laryngeal carcinoma patients enrolled in a pro-
spective, single-arm, single institution Phase II study. In
this trial, response to a single cycle of induction chemo-
therapy was used to select patients for definitive treat-
ment with surgery and radiation versus chemoradiation.4
This study demonstrated that induction chemotherapy
followed by concurrent chemoradiation in responders (lar-
yngectomy in nonresponders) was effective for both organ
sparing (71%) and survival in advanced larynx cancer
with 3-year survival rates of 83%. Tissue microarrays
assembled from pretreatment biopsy specimens from
patients enrolled in this prospective clinical trial were
used to assess biomarker expression. The panel of bio-
markers to evaluate was selected based upon pathways
previously implicated in head and neck carcinogenesis
and treatment response.
Responsible for maintaining cellular integrity, p53
plays a central role in pathways. The p53 network is
activated when cells are damaged or stressed. Upon acti-
vation, the p53 protein can lead to cell cycle arrest and
DNA repair, or it can cause programmed cell death. 5,6
Approximately 50% of head and neck tumors have a p53
mutation. It is p53 that is thought to be one of the
molecular determinants regulating the response to
chemotherapy.
Bcl-xL is a member of the antiapoptotic Bcl-2 pro-
tein family.7–9 Bcl-xL binds proapoptotic proteins such
as BAK via the BH3 domain and prevents these proteins
from initiating apoptosis at the mitochondrial mem-
brane.9,10 Previous work demonstrated that Bcl-xL was
overexpressed in 75% of HNSCC.11 Overexpression of
antiapoptotic proteins such as Bcl-2 and Bcl-xL was fre-
quently associated with chemotherapy and radiation
resistance.7,12
Numerous other biomarkers of interest were also
evaluated for their association with clinical outcomes of
interest. CD24 is a cell surface marker previously shown
to be associated with poor prognosis in many other
tumor types, including ovarian, non-small cell lung,
breast, prostate, and colorectal cancer.13–17 EGFR inten-
sity has been shown to be a marker of poor prognosis in
oropharynx and larynx cancer.18–20 MDM2, an endoge-
nous suppressor of p53, is up-regulated with expression
of functional p53.21–23 BAK is a proapoptotic cytoplasmic
protein that is regulated by p53.24 Nuclear factor kap-
paB (NFjB) is a transcription factor that upregulates
expression of genes that suppress apoptosis and genes
that promote cell cycle progression in cancer cells.25 Pro-
liferating cell nuclear antigen (PCNA) is an antigen
expressed in the nucleus of proliferating cells. RhoC pro-
tein, a known marker of metastases in aggressive breast
cancers and melanoma, has also been found to be over-
expressed in certain head and neck cancers.26–28 Survi-
vin is a member of the inhibitor of apoptosis (IAP)
family. The survivin protein inhibits caspase activation,
thereby leading to negative regulation of apoptosis or
programmed cell death.29
These biomarkers were tested and evaluated for
correlation with survival, disease-free survival, organ
preservation, and chemotherapy response.
MATERIALS AND METHODS
Study Population(s)
Subjects for these analyses signed informed consent to
participate in trial that included analysis of tissue specimens
for biomarker analyses. Specimens were taken from pretreat-
ment biopsies, and during salvage surgery in cases where sal-
vage surgery was performed.
Patient Demographics and Outcomes of Entire
Clinical Trial
The results of the clinical trial were previously published
and are summarized.4 Of 97 eligible patients, 73 (75%) achieved
more than 50% response and received chemoradiotherapy. A
total of 29 patients (30%) had salvage surgery; 19 patients
(20%) had early salvage surgery after the single cycle of induc-
tion chemotherapy, three patients (3%) had late salvage after
chemoradiotherapy, six patients (6%) eventually had salvage
surgery for recurrence, and one patient had laryngectomy for
chondroradionecrosis. The median follow-up time was 41.9
months. The overall survival rate at 3 years is 85%. The
disease-specific survival rate was 87%. Larynx preservation was
achieved in 69 patients (70%).
Tissue Microarray Construction
Formalin-fixed, paraffin-embedded pretreatment tissue
samples were used for the construction of a tissue microarray
(TMA) from this study. A pathologist marked representative
areas of tumor and normal on hematoxylin- and eosin (H&E)-
stained sections from each tissue block. To account for tumor
heterogeneity, three 0.6-mm tumor tissue cylinders were
punched from marked tumor area of each tissue block and
transferred to a recipient block. Cores were also taken from
adjacent normal tissues to serve as internal controls. The first
TMA was fashioned from pretreatment tumor biopsy specimens.
A second TMA was constructed using salvage surgical
specimens.
Immunohistochemistry
A large panel of biomarkers was tested using immunohis-
tochemistry (Table I). The TMA slides were stained for p53 (Ab-
6, clone DO-1, MS-187, 1:100; Lab Vision, Fremont, CA), Bcl-xL
(Ab-2, clone 7D9, MS-1334-PO, 1:100; Lab Vision, Fremont,
CA), Bcl-2 (clone 124, undiluted; Dako, Carpinteria, CA), BAK
(Upstate 06–536, 1:400; Millipore, Temecular, CA), PCNA (18–
8110, 1:500; Zymed, South San Francisco, CA), CD24 (clone
ML5, 1:100; BD, Franklin Lakes, NJ), EGFR (31G7, undiluted;
Zymed Laboratories, South San Francisco, CA), MDM2 (1:200,
stained by MD Anderson, Dr. El-Naggar), NFjB (SC-372, 1:500;
Santa Cruz Biotechnologies, Santa Cruz, CA), RhoC (as previ-
ously described),30 Survivin (clone EP 2880Y, 2463-1, 1:100;
Epitomics, Burlingame, CA), and cyclin D1 (clone SP4, 1:100;
Lab Vision, Fremont, CA). Slides were deparaffinized, rehy-
drated, and heated at 92C in antigen retrieval buffer (Dako,
Carpinteria, CA) for 20 minutes. After cooling to room tempera-
ture for 20 minutes, they were rinsed in PBS and incubated
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with peroxidase block (Dako, Carpinteria, CA) for 5 minutes fol-
lowed by 1.5% horse serum (Vector Laboratories, Burlingame,
CA) in PBS for 30 minutes. Primary antibody, diluted in block-
ing buffer, was added for 1 to 2 hours, washed and incubated
with biotinylated antimouse IgG (ABC Kit; Vector Laboratories,
Burlingame, CA) for 30 minutes. The slides were washed and
incubated with avidin/biotin-conjugated peroxidase for 30
minutes. Color was developed with diaminobenzidine tetrahy-
drochloride (Sigma, Saint Louis, MO) and counterstained with
hematoxylin. They were dehydrated and mounted. Affinity puri-
fied mouse IgG2a (Sigma, Saint Louis, MO) was used as a nega-
tive control.
Immunohistochemical Interpretation
Slides were read by a qualified head and neck pathologist
who was blinded to the clinical outcomes of the patients. Each
core was evaluated for the percentage of tumor cells stained on a
scale of 1 to 4 with 1: <5% staining, 2: 5% to 20% staining, 3:
21% to 50% staining and 4: 51% to 100% staining. In a similar
fashion, cores were evaluated for intensity of immunohistochemi-
cal staining according to the following scale: 1: none, 2: weak, 3:
moderate, and 4: strong. Some biomarkers were evaluated sepa-
rately for nuclear (n) and cytoplasmic (c) staining (MDM2,
NFjB) and for nuclear (n) and surface (s) staining (CD24). EGFR
demionstrated only surface staining. Table I also indicates
whether the biomarker results were evaluated by proportion,
intensity, and/or percent positive cells (counted). PCNA was the
only biomarker evaluated by percent positive cells (counted).
Pattern of Invasion
Pattern of invasion (growth pattern) was scored on H&E–
stained, formalin-fixed sections according to published criteria31
by a pathologist blinded to outcome. Grading of the invasive
front was classified as follows: 1) pushing borders; 2) well-
formed, infiltrating cords; 3) thin, irregular, infiltrating cords;
and 4) small groups and dissociated cells.
p53 Mutation Status
The p53 mutation analysis was performed by amplifying
exons 4–9 with polymerase chain reaction and subsequent DNA
sequencing. The two broad categories of p53 mutation are
mutant and wild-type. The p53 mutations can be further subca-
tegorized as to type of mutation. These types include missense,
deletion, and nonsense.
Statistical Analysis
The mean of biomarker scores across multiple cores from
each subject were calculated and used for statistical analysis.
All biomarkers were tested for correlations with chemotherapy
response; chemo-radiation response; overall survival (OS);
disease-specific survival (DSS); time to indication for surgery
(TIS); and clinical covariates of interest such as age, gender, T
stage, N stage, and smoking status (never/former/current
smoker). Time to event outcomes were defined from date of
diagnosis to date of death for overall survival (OS) and date of
death from cancer for DSS. Failure of induction chemotherapy
leading to surgery per protocol, failure of chemotherapy radia-
tion, and local recurrence were considered event endpoints for
TIS.
To evaluate bivariate associations between markers and
ordinal variables of interest,
the Spearman correlation coefficient was used. For marker
associations with nominal variables, the Wilcoxon rank-sum
test was employed for two-level variables; and the Kruskal-
Wallis test was employed for variables with three or more lev-
els. The Kaplan-Meier method and log-rank test were used to
test for differences in the survival functions between strata
defined by clinical variables.
Cox proportional hazards models were used to relate time-
to-event outcomes to marker levels and other predictors. For
each time-to-event outcome, three models were constructed: 1) a
model with a biomarker alone, 2) a model with clinical variables
alone, and 3) a model with clinical variables and the biomarker.
Models 2 and 3 were used to assess the marker effects beyond
the effects of clinical variables. Likelihood ratio statistics were
used to compare the models.
A mixed model approach was used to determine if there
are significant changes in the mean levels of expression
between pretreatment and salvage specimens. Empiric esti-
mates of the standard errors were explored to avoid bias due to
within-subject variability. For verification, models with a sym-
metric modeling structure were run to explicitly adjust for
within-subject variability in our mixed models.
All statistical analyses were done using SAS v9.232 (Carey,
NC). A two-tailed P value of 0.05 or less is considered to be stat-
istically significant. For each outcome of interest, we tested 12
different biomarkers. Though all of these biomarkers are not
strictly independent, we recognize that Type I error due to mul-
tiple comparisons could be an issue in our analysis and as such,
results should be interpreted with caution. We estimate that it
is possible for one P value to appear significant due to random
chance.
RESULTS
Sample Characteristics of the Study Group
The TMA was constructed with 58 pretreatment
specimens. The subjects who were analyzed on the TMA
did not differ significantly with respect to age, T stage,
N stage, clinical stage, or smoking status from those not
used in the TMA analysis. Significantly more of the non-
TMA subjects responded to chemotherapy (P50.03),
indicating that without all tissue from the whole study
cohort our analysis regarding associations between
TABLE I.
Biomarkers Tested With Immunohistochemistry.
Intensity Scored* Proportion Scored† Percent Positive
BAK BAK
Bcl2 Bcl2
BclxL BclxL
CD24 CD24
EGFR
MDM2 MDM2
NFjB NFjB
p53 p53
PCNA PCNA
RhoC
Survivin Survivin
*Intensity was scored according to the following scale: 15 none;
25weak; 35moderate; 45 high.
†Proportion was scored according to the following scale: 15< 5%;
25 5%–20%; 35 21%–50%; 45 51%–100%.
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biomarkers and induction chemotherapy response may
be biased due to missing data. Table II summarizes the
sample characteristics for those that are and are not
represented in the TMA analysis.
Biomarker Descriptives
Table IIIa shows the proportion of tumor specimens
that demonstrate expression of each individual bio-
marker according to evaluation of intensity and propor-
tion for pretreatment and salvage specimens. Table IIIb
shows the results for PCNA expression, which was eval-
uated as a continuous variable (percent positive cells
according to cell count) .
Evaluation for Change in Biomarker Expression
Between Pretreatment Biopsy and Salvage
Surgery
Pretreatment and salvage tissue evaluations for
EGFR, PCNA, p53, and Bcl-xL expression were available
for analysis. There was no evidence to support a change
in EGFR, PCNA, or p53 expression in pretreatment ver-
sus salvage surgery specimens. There were 29 pretreat-
ment and 33 salvage tissue cores evaluable for Bcl-xL.
Repeated measures analysis revealed a statistically
significant increase in Bcl-xL expression between pre-
treatment and salvage specimens (P50.0003).
P Values for Associations of Evaluated
Biomarkers and Outcomes
Table IIIb shows the P values for each biomarker in
terms of correlations with the following outcomes: over-
all survival, disease-specific survival, time free from
indication for surgery, chemotherapy response, and che-
moradiation response.
Associations with Chemotherapy Response
Higher levels of mean BAK intensity were signifi-
cantly associated with poorer response to induction
chemotherapy (P50.0004, data not shown). A greater
proportion (13/16, 81%) of tumors with aggressive pat-
terns of histologic invasion (growth patterns 3, 4)
responded to induction chemotherapy as compared to
tumors with less aggressive patterns of invasion (growth
patterns 1, 2), of which 27/39 (69%) of tumors responded.
This difference, however, did not reach statistical
TABLE II.
Sample Characteristics From Subjects With and Without Tissue
for TMA Analysis.
Overall
TMA
Analysis
No
TMA P Value
(n5 97) (n5 58) (n5 39)
Age 58.6 57.4 60.5 0.11*
Disease site Glottic 22% 22% 21%
Supraglottic 78% 78% 79% 0.19†
Stage 3 46% 45% 49%
4 54% 55% 51% 0.15†
T T2 8% 10% 5%
T3 57% 52% 64%
T4 35% 38% 31% 0.44‡
N N0 55% 52% 59%
N1 18% 22% 10%
N2 25% 22% 28%
N3 3% 4% 3% 0.48‡
Smoking
history
Never 3% 3% 3%
Past 21% 20% 23%
Current 76% 77% 74% 0.91‡
Response to
induction
chemotherapy
Responder 77% 70% 87%
Nonresponder 23% 30% 13% 0.03†
3-year overall
survival estimate
84% 82% 87% 0.71§
*t test assuming unequal variances.
†Fisher Exact Test.
‡Chi-square with Monte-Carlo estimation for errors.
§Log-rank test for homogeneity of survival distributions.
TABLE IIIA.
Percentage of Pretreatment Tumor Specimens That Express
Biomarker According to Evaluation of Intensity and Proportion.
Pretreatment Salvage
Intensity Proportion Intensity Proportion
% positive % positive % positive % positive
Biomarker
(mean
score> 1)
(mean
prop> 5%)
(mean
score> 1)
(mean
prop> 5%)
MDM2c 57% 47%
MDM2n 48% 24%
BclxL 95% 77% 95% 95%
EGFR 98% 95%
PCNA 93% 90%
BAK 100% 98%
CD24c 80% 72%
CD24s 86% 68%
Bcl2 27% 27%
NFjB 98% 98%
NFjBc 98% 98%
NFjBn 100% 100%
p53 58% 90% 90%
cyclinD1 79% 79%
Survivin 96% 96%
rhoC 82%
C5 cytoplasmic; n5nuclear; prop5proportion; s5 surface.
TABLE IIIB.
PCNA Was Evaluated by Determining Cell Counts to Determine
Percent Positive (pctPos, continuous variable).
Biomarker N Mean (SD)
PCNA pctPos 56 41.17 28.2
pctPos5percent positive; SD5 standard deviation.
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significance (P5 0.18, Fisher Exact Test). Higher levels
of nuclear NFjB proportion was associated with poorer
induction chemotherapy response (P50.03, Spearman).
Associations with Chemoradiation Response
Higher mean intensity of BAK expression was asso-
ciated with poorer induction chemotherapy and chemo-
radiation response (P5 0.0004 and 0.014, respectively,
Wilcoxon test, Fig. 1A and 1B). Higher mean intensity of
cytoplasmic NFjB expression was associated with poorer
chemoradiation response (P5 0.03, Wilcoxon), while
there was no evidence to suggest the same relationship
with nuclear NFjB expression (P50.94, Wilcoxon).
Associations with Overall Survival
Table IV shows the biomarkers with significant
associations to survival outcomes. P values and hazard
ratios were calculated from Cox proportional hazard
models. Expression of cyclin D1 (intensity and propor-
tion) and CD24 cytoplasmic expression (proportion) are
the biomarkers that best predicted overall survival in
this cohort and meet the criteria for significance
P 0.05. Expression of cyclin D1 (intensity) was the best
predictor of poorer overall survival (P5 0.0008, Fig. 2A).
Specifically, high cyclin D1 expression was associated
with increased risk of death (HR 1.993 for cyclin D1
intensity, HR 1.562 for cyclin D1 proportion). In con-
trast, elevated expression cytoplasmic CD24 expression
was associated with lowered risk of death (HR 0.577 for
CD24 proportion, HR 0.616 for CD24 intensity).
Associations with Disease-Specific Survival
Increased expression of cyclin D1 (intensity) shows
the greatest association with an increased risk of death
from disease (P50.0147, HR 1.971, 95% CI 1.143, 3.399,
Fig. 2B). Expression of the epidermal growth factor
receptor (EGFR) was also associated with an increased
risk of death from disease (P5 0.0424, HR 2.47, 95% CI
1.031, 5.917, Fig. 3).
Survival Models
Survival models controlling for stage and for induc-
tion chemotherapy response were tested to determine if
adding biomarker information would be informative. The
addition of cyclinD1 adds predictive information to a
survival model with clinical stage alone (likelihood ratio
test, P value5 0.0025), N-stage alone (likelihood ratio
test, P value5 0.0028), or induction chemotherapy alone
(likelihood ratio test, P value50.0010). Knowing the
clinical stage plus CD24 level is more predictive for over-
all survival than knowing clinical stage alone (likelihood
ratio test, P value5 0.0340), N-stage alone (likelihood
ratio test, P value5 0.0292), or induction chemotherapy
alone (likelihood ratio test, P value5 0.0052). The addi-
tion of cyclinD1 or EGFR adds predictive information to
disease-specific survival models with induction chemo-
therapy alone (likelihood ratio tests, P value50.012 for
cyclinD1, P value5 0.044 for EGFR).
Given the prognostic importance of cyclin D1
expression in determining overall and disease-specific
survival, other biomarkers were tested for association
Fig. 1. (A) Box-whisker plot indicating the association between mean BAK expression intensity and induction chemotherapy response
(CR5 complete response, PR5partial response, SD5 stable disease, PD5progressive disease). Bold lines indicate the median expres-
sion. Boxes indicate the 25th and 75th quartile. Mean BAK intensity of expression increases with poorer response to induction chemother-
apy (P50.0004). (B) Box-whisker plot indicating the association between mean BAK expression intensity and chemoradiation response.
Mean BAK intensity of expression is lower in tumors that responded to chemoradiaiton as compared to tumors that persisted following
chemotherapy and/or radiation (P5 0.014).
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TABLE V.
Biomarkers With Significant Association With Overall Survival.
Marker Total Event
P Value
Marker Alone
Hazard Ratio
(for death)
95% Lower
Confidence Limit
for Hazard Ratio
95% Upper
Confidence Limit
for Hazard Ratio
cyclinD1_inten 57 27 0.0008 1.993 1.33 2.988
CD24c_prop 50 24 0.0255 0.577 0.356 0.935
cyclinD1_prop 57 27 0.031 1.562 1.042 2.343
CD24c_inten 50 24 0.0538 0.616 0.377 1.008
TABLE IV.
P Values for Each Marker According to Outcome Measure.
Marker OS DSS
Time Free From Indication
for Surgery
Induction Chemoradiation
Response
Chemoradiation
Response
cyclinD1 inten 0.0008(2) 0.0147(2) 0.7408 0.616 0.699
CD24c prop 0.0255(1) 0.0826(1) 0.1817(1) 0.837 0.872
cyclinD1 prop 0.0310(2) 0.1222(2) 0.7657 0.762 0.779
CD24c inten 0.0538(1) 0.1825(1) 0.5078 0.415 0.719
p53mut status 0.1045(2) 0.5295 0.2518 0.849 0.341
MDM2n prop 0.1087(1) 0.2199(1) 0.4404 0.22(1) 0.295
CD24s prop 0.1838(1) 0.4135 0.3498 0.621 0.976
EGFR pctPos 0.2229(2) 0.4465 0.434 0.869 0.709
NFjBn inten 0.2262(2) 0.4866 0.8513 1.00 0.939
CD24s inten 0.2363(1) 0.2331(1) 0.1942(1) 0.748 0.642
p53 prop 0.2488(1) 0.4930 0.5655 0.569 0.879
EGFR inten 0.3206 0.0424(2) 0.5693 0.741 0.572
Growth pattern 0.3461 0.2522 0.0557(1) 0.177(1) 0.253
MDM2c prop 0.3578 0.2972 0.9537 0.831 0.708
Survivin inten 0.3974 0.7579 0.5311 0.192 0.27
MDM2 prop 0.4259 0.3824 0.8631 0.735 0.742
MDM2n inten 0.4457 0.3289 0.4667 0.822 0.831
Survivin prop 0.5032 0.7505 0.405 0.358 0.277
BAK inten 0.5143 0.9494 0.0914(2) 0.0004(2) 0.014(2)
Bcl2 inten 0.5609 0.7586 0.4516 0.576 0.969
BclxL inten 0.6636 0.8542 0.439 0.716 0.525
Bcl2 prop 0.6686 0.5084 0.6197 0.567 0.99
MDM2 inten 0.6894 0.3737 0.3545 0.683 0.375
MDM2c inten 0.7088 0.2836 0.2518 0.483 0.193(2)
PCNA pctPos 0.7353 0.6475 0.3544 0.873 0.827
NFjB inten 0.7400 0.8040 0.9245 0.108(2) 0.055(2)
NFjBc inten 0.7401 0.6944 0.8501 0.068(2) 0.033(2)
BclxL prop 0.7802 0.5589 0.5931 0.739 0.183(1)
PCNA inten 0.7835 0.8772 0.1752(1) 0.31 0.637
rhoC inten 0.7915 0.2868 0.4797 0.684 0.949
BAK prop 0.8488 0.7396 0.4844 0.264 0.286
NFjB prop 0.9399 0.3991 0.7361 0.851 0.72
NFjBc prop 0.9572 0.4249 0.6229 0.293 0.233(2)
NFjBn prop 1.0000 0.8829 0.5442 0.073(2) 0.763
Highlighted cells indicate P values: red5< 0.01; yellow5 0.01–0.05; green5 0.05–0.10; blue5 0.10–0.25.
(1)5 higher values of the biomarker, p53 mutation present, or thinner/single cell growth pattern associated with improved survival or better response to
therapy.
(2)5 higher values of the biomarker, p53 mutation present, or thinner/single cell growth pattern associated with worse survival or worse response to
therapy.
C5 cytoplasmic; inten5 intensity; n5 nuclear; p53 mut5p53 mutation; pctPos5percent positive; prop5proportion; s5 surface.
[Color table can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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with cyclin D1 expression. Cyclin D1 expression (inten-
sity and proportion) was related to p53 mutation type.
Specifically, tumors with mutant p53 status had a higher
proportion of cyclin D1 expression as a group (Wilcoxon
test, P5 0.0177). Similarly, tumors harboring mutant
p53 were more likely to have a higher intensity of cyclin
D1 expression (Wilcoxon test, P50.0553).
Association of p53 Expression and p53 Mutation
Type
Tumors with missense p53 mutations were likely to
have p53 overexpression, whereas tumors with deletion
p53 mutations were likely to not express p53 (Kruskal-
Wallis, P5 0.0062, Fig. 4). Tumors with nonsense muta-
tions resulting in early termination had low levels of
p53 expression on average, as did tumors with wild-type
p53.
Associations with Time to Indication
for Surgery
Patients whose tumors showed the least aggressive
invasive front (pattern 1: pushing borders) were more
likely to have local relapse and require laryngectomy
than patients with growth patterns 2 to 4 (Fig. 5,
P5 0.0557). Patients with thin cords (pattern 3) and sin-
gle cell (pattern 4) invasive fronts were less likely to suf-
fer relapse at the primary site (hazard ratio 0.6, 95% CI
0.321, 1.014).
Fig. 2. (A) Kaplan-Meier plot of cyclin D1 expression and overall
survival. There is a statistically significant association between
intensity of cyclin D1 expression and overall survival (P50.0008).
(B) Kaplan-Meier plot of cyclin D1 expression and disease-
specific survival. There is a statistically significant association
between intensity of cyclin D1 expression and disease-free sur-
vival (P50.0147).
Fig. 3. Kaplan-Meier plot of EGFR intensity of expression and
disease-specific survival. There is a statistically significant associ-
ation between EGFR expression and disease-specific survival
(P5 0.0424) .
Fig. 4. Association between proportion of tumor cells expressing
p53 and p53 mutation type. Tumors with missense p53 mutations
had higher levels of p53 expression than tumors with deletion p53
mutations (Kruskal-Wallis, P5 0.0062). Tumors with nonsense
mutations had low levels of p53 expression on average as did
tumors with wild-type p53.
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DISCUSSION
The search for biomarkers predictive of outcome
that will inform treatment decision-making is ongoing.
Many groups have looked to biomarkers to predict which
patients will be best treated surgically, and which
patients will be best treated with nonsurgical
approaches. For these analyses to be valid, they must
evaluate cohorts of patients with similar sites and stages
of tumor treated in systematic ways. Biomarker evalua-
tions that are done on patients enrolled in prospective
clinical trials offer significant advantages in terms of the
ability to control for site, stage, and therapeutic
approach. While the ideal scenario would be to identify a
single biomarker with tremendous power to predict cer-
tain outcomes, no such marker has yet been identified.
This situation is likely due to the complex, multifactorial
nature of tumorigenesis and progression with multiple
pathways implicated.
In addition to adding valuable prognostic informa-
tion beyond stage, analysis of biomarkers can enhance
the identification of critical pathways that would be suit-
able for targeting. For example, novel agents that can
target p53, NFjB, EGFR, cyclin D1, or Bcl-xL/2 might
be particularly effective in specific tumors with altera-
tions in these pathways. These considerations are the
central thesis of personalized strategies for treatment of
cancer and are likely to have greater impact in the very
near future. The important observation that the cell sur-
vival protein, Bcl-xL, demonstrates significantly
increased expression in salvage vs. pretreatment tumor
specimens suggests that Bcl-xL plays an integral role in
tumor resistance and might be an ideal candidate for
targeting. Notably, a small molecule inhibitor of Bcl-xL
is being tested in a novel clinical trial of advanced laryn-
geal cancer. There are many targeted therapeutics in
the pipeline whose role can be better defined by
biomarker-driven, prospective clinical trials.
The identification of cyclin D1 expression as a sig-
nificant predictor of overall and disease-specific survival,
together with the potential that this biomarker has to
add information to our traditional staging system, is a
discovery of significant importance.
CD24 is a novel cancer biomarker recently impli-
cated as a poor prognostic marker in several other solid
malignancies.14,16 CD24 has been implicated as a
metastasis-associated protein that has also been sug-
gested as a stem-cell marker. The observation that cyto-
plasmic expression of CD24 in the present study lowered
the risk of death could suggest that high risk pheno-
types may respond better to chemoradiation regimens as
compared to surgical regimens.
NFjB is aberrantly turned on in most head and
neck squamous cell carcinomas 25 and is a key regulator
of cancer cell survival.33,34 The results presented herein
provide supportive evidence that NFjB may mediate
resistance to induction chemotherapy in larynx cancer.
CONCLUSION
Biomarkers hold promise in adding valuable prog-
nostic information beyond stage in patient cohorts with
advanced larynx cancer who are treated in a uniform
fashion. Furthermore, analysis of biomarkers in larynx
cancer can identify critical pathways involved in therapy
resistance that can be targeted with novel agents. Only
through a better understanding of the biology of treat-
ment response and resistance can inroads be made
toward determining the best treatment approach for the
individual patient.
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